Syncona Limited (SYNC) Ordinary NPV
Sell:200.50p
Buy:201.50p
0
Change:
2.00p
(0.99%)

FTSE 250:0.17%
Market closed |
Prices as at close on 28 June 2022
Prices delayed by at least 15 minutes
|
Switch to live prices
|
- Add to watchlist
- Create an alert
- This stock can be held in a
Sell:200.50p
Buy:201.50p
Change:
2.00p
(0.99%)


Market closed |
Prices as at close on 28 June 2022
Prices delayed by at least 15 minutes
|
Switch to live prices
|
Sell:200.50p
Buy:201.50p
Change:
2.00p
(0.99%)

Market closed |
Prices as at close on 28 June 2022
Prices delayed by at least 15 minutes
|
Switch to live prices
|

The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.
Objective
The investment objective is to deliver superior long-term capital appreciation from investments in life science businesses, leading long-only and alternative investment funds and managed accounts across multiple asset classes. The Company will target an IRR per share across its investment portfolio of 15% p.a. over the long term. Over time, it is intended that the Company should invest the significant majority of its assets in Life Science Investments.
Top 10 holdings currently unavailable.
Sector | Weight |
---|---|
Healthcare | 29.39% |
Country | Weight |
---|---|
United Kingdom | 29.39% |
Fee Structure
The company will pay SIML an annual fee of up to 1.05% p.a. of the NAV of company. The fee will be payable monthly in arrears and each payment shall be calculated using the monthly NAV as at the relevant month end.
Dividend Policy
The Company may pay a dividend at the discretion of the Board. Each dividend paid by the Company will be in the form of scrip as a default, with a cash dividend alternative, under which shareholders may elect to receive cash in place of new Shares. Ords issued pursuant to a scrip dividend are issued at a price based on Ord price. Any such dividend will be paid annually. The Company is not declaring a 2021 dividend.
ASSET SPLIT
Trust Manager
Arabella Cecil
Manager Bio
Not currently available for this investment trust.
Board Of Directors
Melanie GeeChairman, Virginia Holmes, Cristina Csimma, Julie Cherrington, Gian Reverberi, Kemal Malik, Robert Hutchinson
Data policy - All information should be used for indicative purposes only. You should
independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete,
and accepts no responsibility for how it may be used.
Objective, holding data, trust manager and bio information, dividend policy, asset split and fee structure are provided by Morningstar.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.